Featured Research

from universities, journals, and other organizations

Cancer drugs offer new hope for Crohn's disease and sarcoidosis

Date:
December 5, 2010
Source:
Case Western Reserve University
Summary:
A new study offers insight into a new treatment avenue for Crohn's Disease and sarcoidosis. While the loss of NOD2 increases the risk of developing Crohn's disease, increased activity of this gene is also thought to exacerbate symptoms. Scientists have identified two existing FDA-approved drugs that are able to inhibit the activity of NOD2's binding partner, the kinase RIP2, and therefore, also inhibit the activity of NOD2.

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

Related Articles


While the loss of NOD2, the gene studied in the provoking article, increases the risk of developing Crohn's disease, increased activity of this gene is also thought to exacerbate symptoms. Additionally, activating NOD2 mutations can cause genetic sarcoidosis -- an inflammatory disease affecting multiple organs in the body, but primarily the lungs and lymphoid tissue. A Case Western Reserve University School of Medicine research team has identified two existing FDA-approved drugs that are able to inhibit the activity of NOD2's binding partner, the kinase RIP2, and therefore, also inhibit the activity of NOD2. By inhibiting NOD2's signaling pathways through the use of medications, patients with these diseases potentially have a new avenue of treatment.

Over the past decade, drugs targeting protein kinases have been among the most successful pharmacologic agents developed in the treatment of both solid and blood-based cancers. Two of these medications, Tarcevaฎ and Iressaฎ, target the cancer cells' epidermal growth factor receptor (EGF-Receptor) protein kinase to inhibit the growth of both lung cancer and brain cancer. At Case Western Reserve, Drs. Justine Tigno-Aranjuez and Derek Abbott screened known tyronsine kinase inhibitors and found that these two drugs are very potent against RIP2. The researchers discovered that the medications target RIP2 as efficiently as they target the EGF-Receptor. The study further shows that both Tarceva and Iressa both inhibited and diminished the effects of NOD2 hyperactivation.

A difficult step in drug development centers on demonstrating the safety and efficacy of a new drug and ultimately having that drug approved by regulatory agencies. Tarceva and Iressa have been through the clinical regulatory process and have attained FDA approval. Therefore, this opens a door for treatment that, with appropriate preclinical testing for this new function, could be more rapidly translated into clinical treatment. Although preliminary, this work suggests that these FDA-approved drugs may benefit conditions exacerbated by NOD2 hyperactivation, including sarcoidosis.

"While these findings offer a potentially beneficial avenue for the treatment of two serious inflammatory diseases, further testing is necessary to substantiate our initial promising findings. Further testing is also necessary to validate the safety and potential efficacy of these agents in both Crohn's disease and sarcoidosis," states Derek Abbott, MD, PhD, assistant professor of pathology at Case Western Reserve School of Medicine and senior author on the study. "However, these studies also show that very basic biochemical research can lead to findings that could have clinical impact."

In addition to identifying FDA-approved drugs that target the NOD2:RIP2 pathway, this finding also has implications for personalized medicine. "Like many cancer chemotherapeutics, Tarceva and Iressa cause side effects in cancer patients, including skin rash and diarrhea. It would be interesting to determine if these side effects change as a function of a patient's NOD2 status and if the dosing needs to be adjusted in patients with mutant NOD2 versus those with normal NOD2," says personal health expert Kathryn Teng, MD, director of Clinical Integration of Personalized Healthcare at Cleveland Clinic and assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. "Although these results are very preliminary in terms of patient care, their implications for personalized medicine are intriguing and might give a wide variety of reasons to test for NOD2 mutation status in a broader subset of patients."

With an eye toward this future clinical development, Dr. Abbott's team is working with the university's Technology Transfer Office and pharmaceutical companies to further test the clinical potential of their findings.

This study was funded, in part, by grants from the National Institutes of Health and the Burroughs Wellcome Foundation.


Story Source:

The above story is based on materials provided by Case Western Reserve University. Note: Materials may be edited for content and length.


Cite This Page:

Case Western Reserve University. "Cancer drugs offer new hope for Crohn's disease and sarcoidosis." ScienceDaily. ScienceDaily, 5 December 2010. <www.sciencedaily.com/releases/2010/11/101130171958.htm>.
Case Western Reserve University. (2010, December 5). Cancer drugs offer new hope for Crohn's disease and sarcoidosis. ScienceDaily. Retrieved December 21, 2014 from www.sciencedaily.com/releases/2010/11/101130171958.htm
Case Western Reserve University. "Cancer drugs offer new hope for Crohn's disease and sarcoidosis." ScienceDaily. www.sciencedaily.com/releases/2010/11/101130171958.htm (accessed December 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, December 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) — It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) — More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) — In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
The Best Protein-Filled Foods to Energize You for the New Year

The Best Protein-Filled Foods to Energize You for the New Year

Buzz60 (Dec. 19, 2014) — The new year is coming and nothing will energize you more for 2015 than protein-filled foods. Fitness and nutrition expert John Basedow (@JohnBasedow) gives his favorite high protein foods that will help you build muscle, lose fat and have endless energy. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins